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ABSTRACT 
The cyclic AMP phosphodiesterases type 4 (PDE4s) are expressed in a cell 
specific manner, with intracellular targeting directed by unique N-terminal anchor 
domains. All long form PDE4s are phosphorylated and activated by PKA 
phosphorylation within their upstream conserved region 1 (UCR1). Here, we 
identify and characterise a novel PKA site (serine 42) within the N-terminal region 
of PDE4D7, an isoform whose activity is known to be important in prostate 
cancer progression and ischemic stroke. In contrast to the UCR1 site, PKA 
phosphorylation of the PDE4D7 N-terminus appears to occur constitutively and 
inhibits PDE4 activity to allow cAMP signalling under basal conditions. 
  
  
 
1. INTRODUCTION 
3’,5’-cyclic adenosine monophosphate (cAMP) is a ubiquitous intracellular 
second messenger that acts to orchestrate a number of important physiological  
functions that  are triggered by activation of specific cell -surface receptors. 
Specificity of receptor action is often underpinned by the compartmentalisation of 
intermediates within the cAMP-signalling cascade. Discrete positioning of 
enzymes that synthesise cAMP (adenylate cyclase), are activated by cAMP 
(PKA, EPAC and cyclic nucleotide –gated ion channels) or degrade the second 
messenger (phosphodiesterases) allow the cell to tailor cellular responses 
following signals generated by a number of receptors coupled to GαS [1]. The 
duration and strength of signals produced by cAMP effectors is often heavily 
influenced by action of a super-family of enzymes that has evolved to degrade 
cyclic-nucleotides, the phosphodiesterases (PDEs) [2]. 
Of particular interest is the PDE4 family of enzymes, which is made up of 
over 25 different isoforms, many of which have important, non-redundant 
functions [3]. Often, the function of a particular PDE4 isoform is conferred by its 
unique N-terminal, which acts as a “postcode” to anchor PDE4 enzymes to 
discrete intracellular domains where they sculpt signal-specific cAMP gradients. 
PDE4s also contain a catalytic unit and regulatory domains termed “upstream 
conserved regions one and two” (UCR1/2) which are highly conserved 
throughout the isoforms [4]. All long-form PDE4s contain UCR1, which contains a 
PKA motif that becomes phosphorylated during conditions of raised cAMP [5]. 
Such an action serves to activate PDE4 and rapidly reduce the local 
concentration of cAMP. This feedback loop underpins the transient nature of 
cAMP signals and ensures a rapid but fleeting response to activation of GαS-
coupled receptors [6]. 
In addition to phosphorylation of UCR1, the long isoform PDE4D3 
undergoes PKA phosphorylation within its unique N terminus [5]. This 
  
modification does not affect activity but instead increases the affinity of binding to 
the A-kinase anchor protein, mAKAP [7]. To date, this is the only known case of 
a long PDE isoform being phosphorylated by PKA other than within its UCR1 
domain. Using peptide array technology and a novel phospho-specific antibody, 
we demonstrate that PDE4D7, an isoform who’s activity is known to be important 
in prostate cancer progression [8] and ischemic stroke [9], is also phosphorylated 
by PKA within its unique N terminus on serine 42. We show modification of 
PDE4D7 in this way occurs under basal conditions, reduces PDE4D7 activity, 
and we hypothesise that this feature allows basal cAMP signalling, which may be 
necessary for cellular homeostasis and could be involved in the cAMP sensitive 
progression of prostate cancer from the androgen sensitive to androgen 
insensitive state 
 
2. MATERIALS AND METHODS 
2.1 Reagents 
Forskolin (Sigma) and KT5720 (Enzo) were dissolved in dimethyl sulfoxide. Anti-
PKA phospho substrate (RXXpS) antibody was supplied from Cell Signalling, 
USA: Cat. No. 9621. Anti-phospho PDE4D7-serine42 antibody was custom made 
by AMSBIO (Europe) in rabbits against a phosphorylated peptide corresponding 
to residues 34EPYLVRRL(p)SCRN45. Total PDE4D7 antibody was custom made 
by Altabioscience (UK) against a GST-fusion of the whole unique N terminal 
region of PDE4D7.  
2.2 Peptide Array 
Peptide libraries were produced by automatic SPOT synthesis and synthesized 
on continuous cellulose membrane supports on Whatman 50 cellulose 
membranes using Fmoc-chemistry with the AutoSpot-Robot ASS 222 (Intavis 
Bioanalytical Instruments AG, Köln, Germany) as previously described by us 
[10]. PKA phosphorylation of an immobilized library of PDE8 peptides was 
  
undertaken using 100units of purified PKA catalytic subunit (Promega). 
Recombinant kinase was diluted in phosphorylation buffer (20 mM Tris-HCl; pH 
7.5, 10 mM MgCl2, 0.5 mM CaCl2, 1 mM DTT, 0.2 mg/ml BSA, 1 mM ATP) and 
incubated with arrays at 30°C for 30 min with shaking.  
2.3 Site Directed Mutagenesis of PDE4D7 
Site-directed mutagenesis was performed using the Quickchange kit 
(Stratagene) according to manufacturer’s instructions. The following primers 
were used to create the required full length and N terminal mutants. PDE4D7 
S42A mutant, forward primer: 
AGACTTGCATGTCGCAATATTCAGCTTCCCCCTCTC,                                                                                       
reverse primer: 
ATTGCGACATGCAAGTCTCCGGACAAGATAGGGTTCCATTCC.                                                                                       
S42D mutant, forward primer: 
CGGAGACTTGACTGTCGCAATATTCAGCTTCCCCCTCTC,                              
reverse primer: GGGATAGAACAGGCCTCTGAACTGACAGCGTTATAAGTCG. 
2.4 Purification of GST-PDE4D7 S242A 
Briefly; BL21 cells were transformed with the fusion protein and induction was 
brought about by addition of 1mM of isopropyl-β-D-thiogalactopyranoside (IPTG). 
Following protein induction, cells were lysed by sonication and lysate was 
incubated with Glutathione sepharose beads (Amersham). Following an 
incubation period, the beads were washed in elution buffer (50mM Tris pH 8.0) + 
glutathione (6.8mg of reduced glutathione (Sigma) per 1ml of elution buffer). The 
beads were pelleted by brief centrifugation and the eluate was collected. 
Overnight dialysis of the collected eluate was carried out in dialysis buffer 
(100mM NaCl, 50mM Tris-HCl; pH 8.0, 5% glycerol, 5mM DTT) in slide-a-lyzer 
cassettes (Piercenet) at 4oC to remove any detergents or glutathione. Following 
recovery of the eluates from the cassettes, the protein concentration was 
determined by a Bradford assay. 
2.5 In vitro PKA phosphorylation of PDE4D7 
  
Purified (2ug) wt GST-PDE4D7 unique N terminal region and S42A wt GST-
PDE4D7 unique N terminal region (Fig1E/F) or  VSV-pull downs of Wt, S42A and 
S42D transfections (Fig 3C)were incubated with 25 units of purified PKA catalytic 
subunit (Promega) in phosphorylation buffer (20 mM Tris-HCl; pH 7.5, 10 mM 
MgCl2, 0.5 mM CaCl2, 1 mM DTT, 0.2 mg/ml BSA, 1 mM ATP) for 1h at 30°C 
with gentle agitation. The samples were run on an SDS–PAGE gel and 
immunoblotted with the PKA phospho-substrate and phospho-specific antibodies.  
2.6 Cellular transfection of wt and mutant PDE4D7 constructs and cell treatments 
VSV tagged wild type PDE4D7, S42A PDE4D7, S42D PDE4D7 and dnPDE4D7 
were transfected into HEK293 cells using Polyfect transfection reagent (Qiagen). 
Cells were treated with KT5720 (4uM) for 20 min prior to forskolin (100uM) 
treatment for the time points indicated, or forskolin alone (100uM). Control cells 
were treated with DMSO or left untreated (NT). Cell lysates were harvested in 
KHEM buffer (50mM HEPES pH7.4, 50mM KCL, 1.92mM MgCl2) (for PDE 
activity assays) or 3T3 lysis buffer (25mM HEPES, 10% w/v glycerol, 50mM 
NaCl, 1% w/v Triton x100, 50mM NaF, 30mM NaPP, 5mM EDTA, pH7.4) 
containing Complete, EDTA-free Protease Inhibitor Cocktail Tablets (Roche) and 
PhosStop Phosphatase Inhibitor Cocktail Tablets (Roche).  
 
2.7 Phosphodiesterase activity assays 
Phosphodiesterase activity was measured using a radioactive cAMP hydrolysis 
assay that has been described previously [5]. [8-3H] adenosine cyclic-3′,5′-mono-
phosphate was sourced from Amersham Biosciences (Little Chalfont, UK) and 
cyclic-3′,5′-mono-phosphate from Sigma. The substrate concentration used for 
PDE assays was 150 nM, and the specific PDE activity was determined as pmol 
cAMP hydrolysed/min/mg protein. PDE activities were then normalised for 
expression of construct, and the data were normalised to untreated (NT) wild 
type PDE4D7 activity.   
  
 3. RESULTS 
Sequence analysis of the PDE4D7 sequence uncovered a novel, putative 
consensus PKA site in the unique N-terminal region (37LVRRLSCR44) in addition 
to the already known site in UCR1 (125QRRESFL131) (Fig. 1A). To determine 
whether the 4D7 N-terminal motif is a PKA substrate, immobilised peptide array 
libraries of the N-terminal and UCR1 regions were synthesised using peptide 
array. Peptide array has been used by our group to successfully identify 
ubiquitination [11] and SUMOylation [12] sites on PDE4D5, and PKA sites on  
PDE8 [13], PI3K [14] and DNAPK [15]. Peptide arrays of overlapping 25-mer 
peptides, sequentially shifted by 5 amino acids and spanning the PDE4D7 N-
terminal and UCR1 regions were incubated with a PKA assay mix before 
detection of phosphorylation using a PKA phospho-substrate antibody (fig. 1B).  
Only two regions of phosphorylation were detected and these contained the 
previously known PKA site in UCR1 (125QRRESF130) and the new site in the 
unique N-terminal (38VRRLSC43) (Fig. 1B).  No phosphorylation was detected 
when active PKA was omitted from the assay mix (Fig. 1C left panel) and peptide 
spotting was verified by coomassie staining (Fig. 1C right panel). In addition to 
the PKA phospho-substrate antibody, phosphorylation of serine 42 by PKA on 
peptide array was also be detected by a novel phospho-specific antibody raised 
against a peptide containing a phosphorylated version of the 4D7 N-terminal PKA 
site. (Fig. 1D, right panel). No such phosphorylation was detected by pre-immune 
serum or when PKA catalytic subunit was omitted from the assay mix (Fig. 1D 
left and middle panels). 
 
Wild type N-terminal GST-PDE4D7 (WT-NT) and mutant N-terminal GST-
PDE4D7-S42A (S42A-NT) were purified (Fig. 1E) and incubated with a PKA 
assay mix containing active purified PKA catalytic unit. Phosphorylation of the 
serine 42 site in the wild type N-terminal construct was detected by the PKA 
phospho-substrate antibody and our phospho-specific S42 antibody (Fig. 1F). 
However, neither picked up phosphorylation in the S42A mutants (Fig. 1F). 
Gratifyingly, the PKA phospho-substrate antibody also detected auto-
  
phosphorylation of the PKA catalytic unit (Fig. 1F, upper panel, upper band), 
whereas phospho-specific S42 antibody did not. 
  
To determine whether PKA phosphorylation of PDE4D7 at serine 42 could occur 
in a cellular context, HEK293 cells were transfected with VSV-tagged constructs 
of wild type PDE4D7 and the mutants S42A and S42D. Cells were left untreated 
or pre-treated with the PKA inhibitor KT5720, before endogenous cAMP levels 
were elevated using the adenylate cyclase activator forskolin.  Cell lysates were 
then probed with our phospho-specific S42 antibody and an antibody against 
VSV to evaluate protein loading and construct expression (Fig. 2A). Basal levels 
of S42 phosphoryaltion could be detected and these were significantly increased 
following forskolin treatment. The forskolin-induced increase in phosphorylation 
was attenuated in KT pre-treated cells, indicating that PKA was the kinase 
responsible (Fig. 2A). No phosphorylation of PDE4D7 S42 was detected in cells 
expressing the S42A or S42D mutant. A forskolin time course showed that S42 
phosphorylation steadily increased up to 20 minutes( Fig. 2B, upper panel and 
right panel).  As expected, no phosphorylation of the S42A PDE4D7 mutant 
could be detected.  To show that forskolin was active throughout the time course, 
PKA phosphorylation of non-specified substrates could be seen using the PKA 
phospho-substrate antibody (Figure 2B, middle panel). Interestingly, a mutant of 
PDE4D7 carrying a single substitution that renders the enzyme completely 
inactive, resulted in a more robust and sustained phosphorylation of S42 (Fig. 
2C). Presumably, this is because the “dead” enzyme has lost the ability to 
influence local cAMP concentration around it, leading to unfettered 
phosphorylation by PKA. As PDE4D7 activity is significantly down-regulated 
between androgen sensitive and androgen insensitive prostate cancer, and has 
been shown to mediate androgen sensitive prostate cancer cell proliferation [8], 
we were keen to determine if the phosphorylation of PDE4D7 could be observed 
in the androgen sensitive prostate cancer cell lines DuCaP and VCaP. Basal S42 
phosphorylation was detected in both lines and this was increased following 
forskolin treatment and blocked by KT5720 (Fig. 2D). In a manner consistent with 
  
that seen for overexpressed PDE4D7 (Fig 2B), endogenous PDE4D7 in DuCaP 
(Fig. 2E, upper panel) and VCaP cells (Fig. 2E, lower panel) became 
phosphorylated on S42 gradually following forskolin treatment (Fig. 2E).  
 
As All long form PDE4 isozymes are activated following PKA phosphorylation of 
their UCR1 domain [5], creating a feedback loop to bring about cessation of 
cAMP signalling events, we were interested to see if N- terminal phosphorylation 
affected PDE4D7 activity. Lysates isolated from HEK293 cells, which had been 
transfected with VSV-tagged WT or mutant PDE4D7 constructs, were assayed 
for PDE activity, following 5 min forskolin challenge. Transfection efficiency was 
evaluated by Western blotting (Fig 3A, lower panel). As expected, WT PDE4D7 
doubled in activity after forskolin treatment (Fig 3A, bar chart). Interestingly, the 
phospho-resistant S42A mutant exhibited an active phenotype with increased 
basal activity compared to wtPDE4D7 of >170% (p=0.03, ANOVA) and forskolin 
challenge did not further increase its activity (Fig 3A, bar chart). The phospho-
mimetic S42D mutant, on the other hand, showed a small non-significant 
increase in basal activity compared to WT PDE4D7 NT (36%). The activity of this 
mutant was increased to a similar extent as WT PDE4D7 following forskolin 
challenge. We suggest that the hyperactivity associated with the S42A mutant is 
a result of the fact that phosphorylation of this site provides a mode of negative 
regulation for PDE4D7, ablation of which leads to activation. It is noteworthy that 
this site is basally phosphorylated in all of the cell lines investigated here, 
implying that the cell may require an inactive form of PDE4D7 for normal cellular 
homeostasis. We were unable to recreate phosphorylation-dependent enzyme 
inhibition at this site with the phospho-mimic mutant S42D. It behaved in a similar 
way to WT PDE4D7 under both basal conditions and forskolin treatment (Fig 3A, 
bar chart), suggesting that the negative charge introduced by the substitution 
was not sufficient to evoke a functional change. 
Since ablation of Ser42 phosphorylation led to a more active form of PDE4D7, 
we decided to determine whether this would impinge on the phospho-dynamics 
  
of the UCR1 site. Lysates prepared from cells overexpressing WT PDE4D7 and 
the S42A, S42D mutants were immunoblotted for phospho-UCR1 and phospho-
Ser42. In support of the notion that blockade of the S42 phospho-site increases 
enzymatic activity, very little phosphorylation of UCR1 could be detected in the 
S42A mutant, even after 20 minutes forskolin treatment (Fig. 3B, upper panel). 
Presumably, the increase in PDE4 activity conferred by this mutation, acts to 
diminish local cAMP concentrations, in turn, attenuating PKA activity and 
preventing phosphorylation at the UCR1 PKA site, though it is possible that S42A 
directly affects the phosphorylation of UCR1 by PKA as isolated VSV Ips of the 
S42A mutant did not get phosphorylated by active PKA catalytic subunit , 
whereas wild type and S42D mutant did (Fig. 3C). 
 As with activity measurements, the WT PDE4D7 and S42D mutant behaved in a 
similar fashion with respect to UCR1 phosphorylation suggesting that the 
substitution of a negatively charged amino acid at S42 did not mimic the 
phosphorylation. In both cases (WT PDE4D7 and S42D mutant ), no basal UCR1 
phosphorylation could be detected, with a sustained phosphorylation being 
triggered by forskolin.  
4. DISCUSSION 
Fine control of compartmentalised cAMP signalling is underpinned by the 
discrete positioning of phosphodiesterase enzymes which act to both maintain 
basal cAMP concentrations and shape cAMP gradients following activation of cell 
surface receptors [1]. Aberrant signalling within the cAMP signalling system has 
been closely linked with prostate cancer progression [16].  Changes in adenylate 
cyclase activity [17], PKA catalytic subunit expression [18] and most recently 
PDE4 expression [8] have all been observed between androgen-sensitive and 
androgen independent cancer phenotypes.  In the latter case, transcripts from 
three sub-families (PDE4A,PDE4B and PDE4D) were detected, with PDE4D 
being the most highly expressed. Separation of a range of prostate cancer 
models and xenografts into androgen sensitive and androgen independent 
categories showed that PDE4D isoforms were downregulated in the androgen 
  
independent prostate cancer models. PDE4 isoform profiling identified PDE4D7 
as the most important PDE4 isoform in the regulation of prostate cancer growth 
with high expression in androgen sensitive cells and a dramatic decline into 
androgen insensitivity [8]. Inhibition of a PDE4D7 pool sequestered to a sub-
plasma membrane compartment increased prostate cancer cell proliferation and 
PDE4D7 has now been proposed as a novel biomarker for diagnosis of the AI 
prostate cancer phenotype. Investigation into the mechanism behind PDE4D7 
expression changes in prostate cancer cell lines demonstrated that transcription 
from the PDE4D7 locus was not controlled by the androgen receptor directly (8) 
and further studies are required to molecular events leading to changes in 
cellular PDE4D7 levels. 
In this paper we provide evidence of a novel PKA phosphorylation site on 
PDE4D7 that alters its activity. Blockade of the phosphorylation of PDE4D7 on 
serine 42 dramatically increases its activity suggesting that phosphorylation at 
this site serves to inhibit the enzyme. Interestingly, the phosphorylation of 
PDE4D7 on serine 42 can be detected in the prostate cancer cell lines DuCaP 
and VCaP opening up the possibility that this post-translational modification may 
further promote the proliferative signalling observed following a reduction in 
PDE4D7 activity. Presumably, the increases in cAMP caused by this event could 
contribute to the AI phenotype by over exciting the autocrine and paracrine 
signalling systems that support androgen receptor transactivation [19]. More 
specifically, it is likely that membrane bound PDE4D7 regulates the cAMP 
gradients that are formed following activation of various Gαs coupled receptors, 
which are known to signal partly through transactivation of the androgen receptor 
[20]. Recent reports of PDE4B knockdown following oxidative stress challenge 
have also been shown to promote growth of castration-resistant prostate cancer 
cells [21]. Experiments using our phospho- serine 42 specific antibody to screen 
AS and AI cell lines and xenografts may shed more light on the possible 
importance of PDE4D7 phosphorylation  as an contributing event in the 
molecular pathology of prostate cancer. 
  
5. ACKNOWLEDGEMENTS 
This study was supported by the framework of CTMM (The Netherlands), the 
Center for Translational Molecular Medicine, PCMM project (grant 03O-203). 
BBSRC funding to GSB (BB/G01647X/1). 
 
6. REFERENCES 
1.  Baillie, G. S. (2009) Compartmentalized signalling: spatial regulation of cAMP 
by the action of compartmentalized phosphodiesterases, The FEBS journal. 276, 
1790-9. 
2.  Houslay, M. D., Baillie, G. S. & Maurice, D. H. (2007) cAMP-Specific 
phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox 
for generating compartmentalized cAMP signaling, Circulation research. 100, 
950-66. 
3.  Houslay, M. D. (2010) Underpinning compartmentalised cAMP signalling 
through targeted cAMP breakdown, Trends in biochemical sciences. 35, 91-100. 
4.  Francis, S. H., Houslay, M. D. & Conti, M. (2011) Phosphodiesterase 
inhibitors: factors that influence potency, selectivity, and action, Handbook of 
experimental pharmacology, 47-84. 
5.  MacKenzie, S. J., Baillie, G. S., McPhee, I., MacKenzie, C., Seamons, R., 
McSorley, T., Millen, J., Beard, M. B., van Heeke, G. & Houslay, M. D. (2002) 
Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase 
A-mediated phosphorylation of a single serine residue in Upstream Conserved 
Region 1 (UCR1), British journal of pharmacology. 136, 421-33. 
6.  Lee, L. C., Maurice, D. H. & Baillie, G. S. (2013) Targeting protein-protein 
interactions within the cyclic AMP signaling system as a therapeutic strategy for 
cardiovascular disease, Future medicinal chemistry. 5, 451-64. 
7.  Carlisle Michel, J. J., Dodge, K. L., Wong, W., Mayer, N. C., Langeberg, L. K. 
& Scott, J. D. (2004) PKA-phosphorylation of PDE4D3 facilitates recruitment of 
the mAKAP signalling complex, The Biochemical journal. 381, 587-92. 
8.  Henderson, D. J., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G. S. 
& Houslay, M. D. (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is 
downregulated in androgen-independent prostate cancer cells and mediates 
proliferation by compartmentalising cAMP at the plasma membrane of VCaP 
prostate cancer cells, British journal of cancer. 110, 1278-87. 
9.  Gretarsdottir, S., Thorleifsson, G., Reynisdottir, S. T., Manolescu, A., 
Jonsdottir, S., Jonsdottir, T., Gudmundsdottir, T., Bjarnadottir, S. M., Einarsson, 
O. B., Gudjonsdottir, H. M., Hawkins, M., Gudmundsson, G., Gudmundsdottir, H., 
Andrason, H., Gudmundsdottir, A. S., Sigurdardottir, M., Chou, T. T., Nahmias, 
J., Goss, S., Sveinbjornsdottir, S., Valdimarsson, E. M., Jakobsson, F., 
Agnarsson, U., Gudnason, V., Thorgeirsson, G., Fingerle, J., Gurney, M., 
Gudbjartsson, D., Frigge, M. L., Kong, A., Stefansson, K. & Gulcher, J. R. (2003) 
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke, 
Nature genetics. 35, 131-8. 
  
10.  Sin, Y. Y., Edwards, H. V., Li, X., Day, J. P., Christian, F., Dunlop, A. J., 
Adams, D. R., Zaccolo, M., Houslay, M. D. & Baillie, G. S. (2011) Disruption of 
the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the 
beta-agonist induced hypertrophic response in cardiac myocytes, Journal of 
molecular and cellular cardiology. 50, 872-83. 
11.  Li, X., Baillie, G. S. & Houslay, M. D. (2009) Mdm2 directs the ubiquitination 
of beta-arrestin-sequestered cAMP phosphodiesterase-4D5, The Journal of 
biological chemistry. 284, 16170-82. 
12.  Li, X., Vadrevu, S., Dunlop, A., Day, J., Advant, N., Troeger, J., Klussmann, 
E., Jaffrey, E., Hay, R. T., Adams, D. R., Houslay, M. D. & Baillie, G. S. (2010) 
Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 
(PDE4D5) regulates the functional consequences of phosphorylation by PKA and 
ERK, The Biochemical journal. 428, 55-65. 
13.  Brown, K. M., Lee, L. C., Findlay, J. E., Day, J. P. & Baillie, G. S. (2012) 
Cyclic AMP-specific phosphodiesterase, PDE8A1, is activated by protein kinase 
A-mediated phosphorylation, FEBS letters. 586, 1631-7. 
14.  Perino, A., Ghigo, A., Ferrero, E., Morello, F., Santulli, G., Baillie, G. S., 
Damilano, F., Dunlop, A. J., Pawson, C., Walser, R., Levi, R., Altruda, F., 
Silengo, L., Langeberg, L. K., Neubauer, G., Heymans, S., Lembo, G., Wymann, 
M. P., Wetzker, R., Houslay, M. D., Iaccarino, G., Scott, J. D. & Hirsch, E. (2011) 
Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function 
of p110gamma, Molecular cell. 42, 84-95. 
15.  Huston, E., Lynch, M. J., Mohamed, A., Collins, D. M., Hill, E. V., MacLeod, 
R., Krause, E., Baillie, G. S. & Houslay, M. D. (2008) EPAC and PKA allow cAMP 
dual control over DNA-PK nuclear translocation, Proceedings of the National 
Academy of Sciences of the United States of America. 105, 12791-6. 
16.  Merkle, D. & Hoffmann, R. (2011) Roles of cAMP and cAMP-dependent 
protein kinase in the progression of prostate cancer: cross-talk with the androgen 
receptor, Cellular signalling. 23, 507-15. 
17.  Flacke, J. P., Flacke, H., Appukuttan, A., Palisaar, R. J., Noldus, J., 
Robinson, B. D., Reusch, H. P., Zippin, J. H. & Ladilov, Y. (2013) Type 10 
soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls 
proliferation of prostate cancer cells, The Journal of biological chemistry. 288, 
3126-35. 
18.  Kvissel, A. K., Ramberg, H., Eide, T., Svindland, A., Skalhegg, B. S. & 
Tasken, K. A. (2007) Androgen dependent regulation of protein kinase A 
subunits in prostate cancer cells, Cellular signalling. 19, 401-9. 
19.  Gutierrez-Canas, I., Rodriguez-Henche, N., Bolanos, O., Carmena, M. J., 
Prieto, J. C. & Juarranz, M. G. (2003) VIP and PACAP are autocrine factors that 
protect the androgen-independent prostate cancer cell line PC-3 from apoptosis 
induced by serum withdrawal, British journal of pharmacology. 139, 1050-8. 
20.  Kasbohm, E. A., Guo, R., Yowell, C. W., Bagchi, G., Kelly, P., Arora, P., 
Casey, P. J. & Daaka, Y. (2005) Androgen receptor activation by G(s) signaling 
in prostate cancer cells, The Journal of biological chemistry. 280, 11583-9. 
21.  Kashiwagi, E., Shiota, M., Yokomizo, A., Itsumi, M., Inokuchi, J., Uchiumi, T. 
& Naito, S. (2012) Downregulation of phosphodiesterase 4B (PDE4B) activates 
  
protein kinase A and contributes to the progression of prostate cancer, The 
Prostate. 72, 741-51. 
 
Figure 1.  (A) Schematic depicting the domain structure of PDE4D7 including 
isoform specific N-terminal region (N-term), Upstream conserved regions 1 and 2 
(UCR1/2) and the catalytic region. (B) Peptide arrays containing immobilised 
peptides corresponding to the regions of the PDE4D7 N-terminal and UCR1 were 
subjected to phosphorylation following incubation with the PKA catalytic subunit. 
Phosphorylation (dark spots) was detected using a phospho-PKA substrate 
antibody. (C) Controls for the experiment described in 1B. The experiment was 
conducted without the catalytic subunit of PKA (left panel) and the presence of 
peptides was detected using Coomassie (right panel). (D) Validation of a novel 
Serine 24 phospho-specific antibody. The Serine 42 phospho-specific antibody 
(right panel) or pre-immune serum (left panel) was used to detect phosphorylated 
peptides on peptide arrays corresponding to the PDE4D7 N-terminal. An 
experimental control conducted without the catalytic subunit of PKA  was also 
undertaken (middle panel). (E) GST-fusion constructs (wild type and S42A) 
corresponding to the N-terminal region of PDE4D7 were purified and (F) used in 
a phosphorylation assay conducted with the catalytic subunit of PKA. The 
phosphorylation of GST-fusion constructs was detected using the Serine 42 
phospho-specific antibody or phospho-PKA substrate antibody. All data in Figure 
1 typical of n=3. 
Figure 2. (A) HEK293 cells were transfected with VSV-tagged PDE4D7 wild type 
or the S42A or S42D mutants and treated with Forskolin or Forskolin after a 
pretreatment with the PKA inhibitor KT5720. Cellular lysates were blotted with 
Serine 42 phospho-specific antibody or VSV antibody. Quantifications on right 
panel. *=p<0.05 (B) HEK293 cells were transfected with VSV-tagged PDE4D7 
wild type or the S42A mutant and treated with Forskolin over 20 minutes. Cellular 
lysates were blotted with Serine 42 phospho-specific antibody or phospho-PKA 
substrate antibody or VSV antibody. Quantifications on right panel. *=p<0.05 (C) 
HEK293 cells were transfected with VSV-tagged PDE4D7 wild type or the 
  
dominant negative, catalytically inactive mutant (D/N) and treated with Forskolin 
over 20 minutes. Cellular lysates were blotted with Serine 42 phospho-specific 
antibody or VSV antibody. (D) DuCaP and VCaP cells and treated with Forskolin 
or Forskolin after a pretreatment with the PKA inhibitor KT5720. Cellular lysates 
were blotted with Serine 24 phospho-specific antibody orPDE4D7 antibody. (E) 
DuCaP and VCaP cells were treated with Forskolin over 20 minutes. Cellular 
lysates were blotted with Serine 42 phospho-specific antibody or PDE4D7 
antibody or GAPDH antibody. All data in Figure 2 typical of n=3. 
 
Figure 3. (A) HEK293 cells were transfected with VSV-tagged PDE4D7 wild type 
or the S42A or S42D mutants and treated with Forskolin. Cellular lysates were 
blotted for VSV or GAPDH.  The PDE activity of cellular lysates was determined 
and expressed as a percentage of wild type control. ANOVA was used to 
determine significance of change (n=3). (B) HEK293 cells were transfected with 
VSV-tagged PDE4D7 wild type or the S42A or S42D mutants and treated with 
Forskolin over a 20 minute time course. Cellular lysates were blotted with Serine 
42 phospho-specific antibody or VSV antibody or a phospho-UCR1 (S129) 
antibody. Data typical of n=3. (C) VSV-tagged PDE4D7 wild type or the S42A or 
S42D mutants were pulled down from transfected HEK293 and subjected to 
phosphorylation by PKA catalytic unit.  Ips were blotted with a phospho-UCR1 
(S129) antibody or VSV. Data for each of three replicates is shown. 
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HIGHLIGHTS 
• PDE4D7 is phosphorylated by PKA in the unique N-terminal region at Serine 42.  
• PDE4D7 phosphorylation at Serine 42 negatively regulates PDE4 activity. 
• Ablation of phosphorylation at Serine 42 activates PDE4D7 and this reduces 
phosphorylation in the UCR1 domain. 
 
 
